Cargando…

Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors

Immunotherapy, represented by immune checkpoint inhibitors (mainly referring to programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockades), derives durable remission and survival benefits for multiple tumor types including digestive system tumors [gastric cancer (GC), colorectal cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhu, Yang, Biao, Liao, Zhengyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991593/
https://www.ncbi.nlm.nih.gov/pubmed/33777812
http://dx.doi.org/10.3389/fonc.2021.650481
_version_ 1783669206834741248
author Zeng, Zhu
Yang, Biao
Liao, Zhengyin
author_facet Zeng, Zhu
Yang, Biao
Liao, Zhengyin
author_sort Zeng, Zhu
collection PubMed
description Immunotherapy, represented by immune checkpoint inhibitors (mainly referring to programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockades), derives durable remission and survival benefits for multiple tumor types including digestive system tumors [gastric cancer (GC), colorectal cancer (CRC), and hepatocellular carcinoma (HCC)], particularly those with metastatic or recurrent lesions. Even so, not all patients would respond well to anti-programmed death-1/programmed death-ligand 1 agents (anti-PD-1/PD-L1) in gastrointestinal malignancies, suggesting the need for biomarkers to identify the responders and non-responders, as well as to predict the clinical outcomes. PD-L1expression has increasingly emerged as a potential biomarker when predicting the immunotherapy-based efficacy; but regrettably, PD-L1 alone is not sufficient to differentiate patients. Other molecules, such as tumor mutational burden (TMB), microsatellite instability (MSI), and circulating tumor DNA (ctDNA) as well, are involved in further explorations. Overall, there are not still no perfect or well-established biomarkers in immunotherapy for digestive system tumors at present as a result of the inherent limitations, especially for HCC. Standardizing and harmonizing the assessments of existing biomarkers, and meanwhile, switching to other novel biomarkers are presumably wise and feasible.
format Online
Article
Text
id pubmed-7991593
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79915932021-03-26 Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors Zeng, Zhu Yang, Biao Liao, Zhengyin Front Oncol Oncology Immunotherapy, represented by immune checkpoint inhibitors (mainly referring to programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockades), derives durable remission and survival benefits for multiple tumor types including digestive system tumors [gastric cancer (GC), colorectal cancer (CRC), and hepatocellular carcinoma (HCC)], particularly those with metastatic or recurrent lesions. Even so, not all patients would respond well to anti-programmed death-1/programmed death-ligand 1 agents (anti-PD-1/PD-L1) in gastrointestinal malignancies, suggesting the need for biomarkers to identify the responders and non-responders, as well as to predict the clinical outcomes. PD-L1expression has increasingly emerged as a potential biomarker when predicting the immunotherapy-based efficacy; but regrettably, PD-L1 alone is not sufficient to differentiate patients. Other molecules, such as tumor mutational burden (TMB), microsatellite instability (MSI), and circulating tumor DNA (ctDNA) as well, are involved in further explorations. Overall, there are not still no perfect or well-established biomarkers in immunotherapy for digestive system tumors at present as a result of the inherent limitations, especially for HCC. Standardizing and harmonizing the assessments of existing biomarkers, and meanwhile, switching to other novel biomarkers are presumably wise and feasible. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7991593/ /pubmed/33777812 http://dx.doi.org/10.3389/fonc.2021.650481 Text en Copyright © 2021 Zeng, Yang and Liao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zeng, Zhu
Yang, Biao
Liao, Zhengyin
Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
title Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
title_full Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
title_fullStr Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
title_full_unstemmed Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
title_short Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
title_sort biomarkers in immunotherapy-based precision treatments of digestive system tumors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991593/
https://www.ncbi.nlm.nih.gov/pubmed/33777812
http://dx.doi.org/10.3389/fonc.2021.650481
work_keys_str_mv AT zengzhu biomarkersinimmunotherapybasedprecisiontreatmentsofdigestivesystemtumors
AT yangbiao biomarkersinimmunotherapybasedprecisiontreatmentsofdigestivesystemtumors
AT liaozhengyin biomarkersinimmunotherapybasedprecisiontreatmentsofdigestivesystemtumors